Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dostarlimab - AnaptysBio/TESARO

Drug Profile

Dostarlimab - AnaptysBio/TESARO

Alternative Names: ANB 011; GSK-4057190; TSR-042; WBP-285

Latest Information Update: 22 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Developer European Network of Gynaecological Oncological Trial Groups; GlaxoSmithKline; Gynecologic Oncology Group; TESARO; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Cervical cancer; Liver cancer; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 18 Nov 2019 Tesaro plans a phase II trial for Rectal adenocarcinoma (Combination therapy, Late-stage disease, Neoadjuvant therapy) in USA (IV) (NCT04165772)
  • 04 Nov 2019 Phase-II clinical trials in Liver cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT03680508)
  • 25 Oct 2019 TESARO plans a phase II trial for Malignant melanoma (Late-stage disease, Neoadjuvant therapy, Monotherapy, Combination therapy) in USA December 2019 (NCT04139902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top